Boustead Singapore's (SGX:F9D) real estate solutions division business secured a major design-and-build contract for an integrated pharmaceutical manufacturing and R&D facility situated within Tuas Biomedical Park, Singapore, according to a Friday filing with the Singapore Exchange.
The project is expected to complete by the third quarter of 2026 and takes the real estate solutions division's order backlog to SG$249 million and the group's engineering order backlog to SG$428 million, the filing said.